相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo
Peibin Yue et al.
CANCER RESEARCH (2016)
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
M. Buchert et al.
ONCOGENE (2016)
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function
Laurence Booth et al.
ONCOTARGET (2016)
[Pemetrexed plus Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling
Laurence Booth et al.
ONCOTARGET (2016)
Ruxolitinib synergizes with DMF to kill via BIM plus BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
Mehrad Tavallai et al.
ONCOTARGET (2016)
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
Laurence Booth et al.
ONCOTARGET (2016)
Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
Greg L. Plosker
DRUGS (2015)
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors
Pawel Gunerka et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2(+) breast cancers
Ruth Rodriguez-Barrueco et al.
GENES & DEVELOPMENT (2015)
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside
Yoshiya Tanaka
JOURNAL OF BIOCHEMISTRY (2015)
Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
Mehrad Tavallai et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation
Sachin K. Deshmukh et al.
ONCOTARGET (2015)
Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells
Hossein A. Hamed et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
D. Zhao et al.
ONCOGENE (2015)
A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation
Erik A. Nelson et al.
Oncotarget (2015)
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors
Laurence Booth et al.
CANCER BIOLOGY & THERAPY (2014)
Met endosomal signalling: In the right place, at the right time
Rachel Barrow-McGee et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
STAT signaling in mammary gland differentiation, cell survival and tumorigenesis
S. Haricharan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer
Sarah R. Walker et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
XPO1 ( CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
Yan Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2014)
p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth
Mercedes Tkach et al.
ENDOCRINE-RELATED CANCER (2013)
Tanshinone IIA Inhibits Breast Cancer Stem Cells Growth In Vitro and In Vivo Through Attenuation of IL-6/STAT3/NF-kB Signaling Pathways
Caiyu Lin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
Junaid Abdulghani et al.
PLOS ONE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells
Gangadharan B. Sajithlal et al.
MOLECULAR PHARMACOLOGY (2013)
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas et al.
CLINICAL CANCER RESEARCH (2012)
Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors
Yong Tang et al.
MOLECULAR PHARMACOLOGY (2012)
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death
Clint Mitchell et al.
CANCER BIOLOGY & THERAPY (2011)
Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells
M. Danielle Bareford et al.
CANCER RESEARCH (2011)
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo
Clint Mitchell et al.
CANCER BIOLOGY & THERAPY (2010)
Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species-Dependent Signaling Pathway
Margaret A. Park et al.
CANCER RESEARCH (2010)
Protein-tyrosine Phosphatase PTPN9 Negatively Regulates ErbB2 and Epidermal Growth Factor Receptor Signaling in Breast Cancer Cells
Taichang Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species
Teneille Walker et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation
Guo Zhang et al.
CLINICAL CANCER RESEARCH (2008)
分享论文
